Pharmacologic Stabilization and Management of Acute Heart Failure Syndromes in the Emergency Department

James D Kirk, John T. Parissis, Gerasimos Filippatos

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Effective use of diuretics, vasodilators, and inotropes to stabilize acute heart failure (AHF) relies on matching the most appropriately tailored therapy to specific clinical profiles. Some of the drugs may be harmful, and therefore the emphasis should be on patient safety and the attempt to minimize the deleterious effects of these therapies. To date, successful treatment has been limited because no agent has been shown to reduce postdischarge mortality or readmission rates, and patients frequently remain symptomatic after treatment. Ongoing research is needed to further examine these agents and to develop novel therapies to address the unmet needs of the patient who has AHF.

Original languageEnglish (US)
Pages (from-to)43-54
Number of pages12
JournalHeart Failure Clinics
Volume5
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Hospital Emergency Service
Heart Failure
Therapeutics
Patient Readmission
Patient Safety
Vasodilator Agents
Diuretics
Mortality
Research
Pharmaceutical Preparations

Keywords

  • Emergency department
  • Heart failure
  • Therapeutic options

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacologic Stabilization and Management of Acute Heart Failure Syndromes in the Emergency Department. / Kirk, James D; Parissis, John T.; Filippatos, Gerasimos.

In: Heart Failure Clinics, Vol. 5, No. 1, 01.2009, p. 43-54.

Research output: Contribution to journalArticle

@article{27126df0c5ba4024967cae8ea80ceb8b,
title = "Pharmacologic Stabilization and Management of Acute Heart Failure Syndromes in the Emergency Department",
abstract = "Effective use of diuretics, vasodilators, and inotropes to stabilize acute heart failure (AHF) relies on matching the most appropriately tailored therapy to specific clinical profiles. Some of the drugs may be harmful, and therefore the emphasis should be on patient safety and the attempt to minimize the deleterious effects of these therapies. To date, successful treatment has been limited because no agent has been shown to reduce postdischarge mortality or readmission rates, and patients frequently remain symptomatic after treatment. Ongoing research is needed to further examine these agents and to develop novel therapies to address the unmet needs of the patient who has AHF.",
keywords = "Emergency department, Heart failure, Therapeutic options",
author = "Kirk, {James D} and Parissis, {John T.} and Gerasimos Filippatos",
year = "2009",
month = "1",
doi = "10.1016/j.hfc.2008.08.003",
language = "English (US)",
volume = "5",
pages = "43--54",
journal = "Heart Failure Clinics",
issn = "1551-7136",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Pharmacologic Stabilization and Management of Acute Heart Failure Syndromes in the Emergency Department

AU - Kirk, James D

AU - Parissis, John T.

AU - Filippatos, Gerasimos

PY - 2009/1

Y1 - 2009/1

N2 - Effective use of diuretics, vasodilators, and inotropes to stabilize acute heart failure (AHF) relies on matching the most appropriately tailored therapy to specific clinical profiles. Some of the drugs may be harmful, and therefore the emphasis should be on patient safety and the attempt to minimize the deleterious effects of these therapies. To date, successful treatment has been limited because no agent has been shown to reduce postdischarge mortality or readmission rates, and patients frequently remain symptomatic after treatment. Ongoing research is needed to further examine these agents and to develop novel therapies to address the unmet needs of the patient who has AHF.

AB - Effective use of diuretics, vasodilators, and inotropes to stabilize acute heart failure (AHF) relies on matching the most appropriately tailored therapy to specific clinical profiles. Some of the drugs may be harmful, and therefore the emphasis should be on patient safety and the attempt to minimize the deleterious effects of these therapies. To date, successful treatment has been limited because no agent has been shown to reduce postdischarge mortality or readmission rates, and patients frequently remain symptomatic after treatment. Ongoing research is needed to further examine these agents and to develop novel therapies to address the unmet needs of the patient who has AHF.

KW - Emergency department

KW - Heart failure

KW - Therapeutic options

UR - http://www.scopus.com/inward/record.url?scp=56049112990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049112990&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2008.08.003

DO - 10.1016/j.hfc.2008.08.003

M3 - Article

C2 - 19026385

AN - SCOPUS:56049112990

VL - 5

SP - 43

EP - 54

JO - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 1

ER -